Skip to Content
Global News Select

Trending: BioNTech Expects Demand Increase in 4Q Despite Lower Earnings

BioNTech is among the most-mentioned companies across news items over the past 12 hours, according to Factiva data, after it said that it expects its variant-adapted Covid-19 vaccine to boost demand later in the year. The German biotechnology company reported lower earnings and revenue for the second quarter but said that it expects vaccine demand in important markets to pick up in the final quarter of the year. The shot, which is still pending regulatory approval, has been adapted for the Omicron variant of Covid-19. BioNTech reported profit of EUR1.67 billion in the second quarter, down from EUR2.79 billion the previous year, on revenue which fell to EUR3.2 billion from EUR5.31 billion in the same quarter a year prior. Dow Jones & Co. owns Factiva.(


(END) Dow Jones Newswires

August 08, 2022 10:49 ET (14:49 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.